Recent Finacing
Recent Raise
Akashi Therapeutics is a clinical-stage biopharmaceutical company developing oral HT-100 (delayed-release halofuginone) to reduce fibrosis and inflammation and promote muscle regeneration in Duchenne muscular dystrophy, conducting phase 1b/2a trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor